Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy

NCT01051063 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01051063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01051063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy
Lead sponsor
GlaxoSmithKline
Phase
Phase 1
Overall status
Completed
Start date
December 9, 2009
Completion date
April 26, 2016
Enrollment
17 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

leukaemia, myelocytic, acute